Clinical Trial Update: Infusion of Donor Lymphocytes Transduced With the Suicide Gene HSV TK in Patients With Haematological Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update on HSV-TK gene-transduced donor lymphocytes for hematologic malignancies; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• Donor Lymphocytes Transduced With HSV-TK (donor lymphocytes transduced with herpes simplex virus thymidine kinase gene)

Snippet

Sponsor: AGC Biologics S.p.A. | Conditions: Hematological Malignancies | Phase 1, Phase 2 | Status: COMPLETED